Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
42.28
+0.38 (0.91%)
At close: Dec 31, 2025, 4:00 PM EST
41.65
-0.63 (-1.49%)
After-hours: Dec 31, 2025, 7:11 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,026,230
Profits / Employee
-$1,979,279
Market Cap
860.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NKTR News
- 15 days ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha
- 16 days ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript - Seeking Alpha
- 16 days ago - Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion - Benzinga
- 17 days ago - Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - PRNewsWire
- 27 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets - Seeking Alpha
- 7 weeks ago - Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout - Seeking Alpha
- 7 weeks ago - New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - PRNewsWire